Established Regulatory Pathways
Not only does plant-based protein expression solve many protein production challenges, the approach is also well-recognized by the FDA, EMA, and other global regulatory bodies.
In fact, in July 2016, the FDA granted orphan drug designation to iBio's investigational biotherapeutic product iBio-CFB03, for the treatment of systemic sclerosis.
Other therapeutics produced by plant-based protein production methods treat a range of conditions including Gaucher disease, Ebola infection, influenza, canine gingivitis, Non-Hodgkin's Lymphoma, and numerous others.
